1. Generics Bulletin

Amgen Hit With US Eylea Suit Ahead Of Looming Biosimilar Date

California-Based Firm Submitted Aflibercept Application Late Last Year

 
• By Dean Rudge

Regeneron is continuing to keep the pressure on would-be biosimilar sponsors for its mammoth Eylea (aflibercept) brand, suing biosimilar sponsor Amgen for alleged patent infringement on the back of a recent favorable verdict over Biocon.

• Source: Shutterstock

Weeks after Amgen confirmed that its proposed biosimilar to Eylea (aflibercept) had been accepted for filing by the US Food and Drug Administration, the California-based firm has been sued for patent infringement by originator Regeneron, in a bid to put the kibosh on Amgen’s ambitions ahead of Eylea’s regulatory exclusivity expiring in May.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products